Clinical trial · Interventional
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients
Phase I Trial of AVD Plus Lenalidomide (Revlimid) in Elderly Intermediate or Advanced Stage Hodgkin Lymphoma Patients
NCT01056679CI-TRIAL-00032205AVD-RevcompletedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicine | Drug | Doxorubicin | ALIAS |
| DTIC | Drug | Dacarbazine | ALIAS |
| Lenalidomide | Drug | Lenalidomide | ALIAS |
| Vinblastine | Drug | Vinblastine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- AVD-Rev
- description
- Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results
- interventionNames
- Drug: Doxorubicine
- Drug: DTIC
- Drug: Lenalidomide
- Drug: Vinblastine
Primary outcomes (1)
- measure
- Dose limiting toxicities (DLT)
Secondary outcomes (2)
- measure
- Overall response rate (ORR)
- measure
- Progression free survival (PFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Hodgkin Lymphoma, intermediate or advanced stage * Age \>60 and \<75 years * ECOG 2 or better * No major organ dysfunction * Ability to take aspirin or LMW Heparin Exclusion Criteria: * HL as composite lymphoma * Prior use of lenalidomide * Prior use of chemo- or radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.